Figure 1

Treatment history of six patients who experience decrease in tumor marker levels during immunization. Case 1 has received tegafur/uracil (UFT) at a daily dose of 600 mg for eight months as oral adjuvant chemotherapy. Case 3 received tegafur/uracil (UFT) at a daily dose of 600 mg for two years as oral adjuvant chemotherapy. Case 5 received 5-FU at a daily dose of 200 mg for three years as oral adjuvant chemotherapy. Case 6 received 2 courses of CPT-11 (40 mg/day) every 4 weeks as adjuvant chemotherapy. Case 7 received 2 courses of leucovorin (750 mg/day) and 5-FU (250 mg/day) every 4 weeks as adjuvant chemotherapy. Case 9 was treated with CPT-11 (40 mg/day) weekly and 5'-DFUR (800 mg/day) for a year as adjuvant chemotherapy. They all had recurrences after the above adjuvant chemotherapy and received peptide-based vaccination without additional chemotherapy.